Editas Medicine Inc(EDIT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.74 | Insider Own | 9.8% | Shs Outstand | 153.5M | Perf Week | -0.83% |
| Market Cap | 0.37B | Forward P/E | - | EPS next Y | 8.61% | Insider Trans | -0.19% | Shs Float | 138.5M | Perf Month | -6.98% |
| Enterprise Value | 0.23B | PEG | - | EPS next Q | -0.19 | Inst Own | 69.24% | Short Float | 26.79% | Perf Quarter | -8.4% |
| Income | -0.07B | P/S | 7.84 | EPS this Y | 56.83% | Inst Trans | 22.51% | Short Ratio | 14.67 | Perf Half Y | -16.96% |
| Sales | 0.05B | P/B | 3.5 | EPS next 5Y | 25.35% | ROA | -33.02% | Short Interest | 37.11M | Perf YTD | 17.07% |
| Book/sh | 0.69 | P/C | 1.74 | EPS past 3/5Y | 17.49% 1.84% | ROE | -118.82% | 52W High | -39.09% ($3.94) | Perf Year | -35.48% |
| Cash/sh | 1.38 | P/FCF | - | Sales past 3/5Y | 27.15% -14.89% | ROIC | -45.5% | 52W Low | 44.58% ($1.66) | Perf 3Y | -63.13% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 73.89% | Gross Margin | 94.84% | Volatility(W/M) | 6.57% 7.24% | Perf 5Y | -93.67% |
| Dividend TTM | - | EV/Sales | 4.85 | Sales Y/Y TTM | 20.83% | Oper. Margin | -177.56% | ATR (14) | 0.19 | Perf 10Y | -82.86% |
| Dividend Ex-Date | - | Quick Ratio | 3.19 | EPS Q/Q | 75.77% | Profit Margin | -157.32% | RSI (14) | 42.33 | Recom | 2 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.19 | Sales Q/Q | 232.31% | SMA20 | -6.55% ($2.57) | Beta | 2.1 | Target Price | $5.11 |
| Payout | - | Debt/Eq | 0.68 | Earnings | 2026/8/5 | SMA50 | -13.52% ($2.78) | Rel Volume | 0.53 | Prev Close | $2.4 |
| Employees | 87 | LT Debt/Eq | 0.54 | EPS/Sales Surpr. | 44.55% 317.74% | SMA200 | -10.04% ($2.67) | Avg Volume(3M) | 2.53M | Price | $2.4 |
| IPO | 2016/2/3 | Option/Short | Yes/Yes | Trades | 5016 | Volume | 1,350,946 | Change | - |
🧬 A clinical-stage biotech company developing next-generation therapeutics based on CRISPR gene-editing technology. Headquartered in the United States, it has secured core Cas9 and Cas12a patent licenses from the Broad Institute and Harvard, placing it among the leading groups in the gene-editing field.
Over the past 1 year, roughly in the middle
39% below its 1-year high.
Traded less than usual. That is 53% of its average volume.
EDIT has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +56.8% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $784. Peers typically go for $1,213.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -93.7%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
26.8% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
WDNA WisdomTree BioRevolution Fund <0.01% 
QQQS Invesco NASDAQ Future Gen 200 ETF <0.01% 
MEDX Horizon Kinetics Medical ETF <0.01% 
NXTE AXS Green Alpha ETF <0.01% 
GNOM Global X Genomics & Biotechnology ETF <0.01% Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
VPC Virtus Private Credit Strategy ETF 27M 
PCR Simplify VettaFi Private Credit Strategy ETF 2M It ranks #241 of 594 in the industry
Based on market cap of $369M.
YDES#239 YD Bio Ltd $375M PER - 
RZLT#240 Rezolute Inc $370M PER - EDIT#241 Editas Medicine Inc $369M PER - 
CCCC#242 C4 Therapeutics Inc $367M PER - 
AVTX#243 Avalo Therapeutics Inc $363M PER - 
FAQ
What kind of company is EDIT?
EDIT belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of EDIT?
The market cap of EDIT is approximately $369M, ranking 3,386 within its sector.
What is the 52-week high and low for EDIT?
EDIT has recorded a 52-week high of $3.94 and a low of $1.66.
